- Home
- VRDN vs BOBS Comparison
VRDN vs BOBS Comparison
Compare VRDN & BOBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$28.67
N/A
Current Price
$15.38
Company Overview
Basic Information| Metric | VRDN | BOBS |
|---|---|---|
| Founded | 2006 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.1B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRDN | BOBS |
|---|---|---|
| Price | $28.67 | $15.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $40.92 | $26.28 |
| AVG Volume (30 Days) | ★ 1.0M | 843.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,706,000.00 | N/A |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | $331.57 | N/A |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.90 | $16.43 |
| 52 Week High | $34.29 | $23.11 |
Technical Indicators
Market Signals| Indicator | VRDN | BOBS |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 35.92 |
| Support Level | $26.31 | N/A |
| Resistance Level | $33.71 | $21.19 |
| Average True Range (ATR) | 1.58 | 1.44 |
| MACD | 0.04 | -0.60 |
| Stochastic Oscillator | 52.01 | 3.26 |
Price Performance
Historical Comparison VRDN
BOBS
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).